References
- McConnell JD. Epidemiology, etiology, pathophysiology and diagnosis of benign prostatic hyperplasia. In: Welsh PC, Retik AB, Vaughan ED et al, Editors. Campbell's Urology, 7th edn. Philadelphia, PA: WB Sanders, 1998: 429-452.
- Yoshimura K, Ohara H, Ichioka K et al. Nocturia and benign prostatic hyperplasia. Urology 2003; 61: 786–790.
- Jacobsen SJ, Guess HA, Panser L et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmstead County study of urinary symptoms and health status among men. Archives of Family Medicine 1993; 2: 729–735.
- Quek KF, Low WY, Razack AH et al. The quality of life outcome following treatment for lower urinary tract symptoms. Asia-Pacific Journal of Public Health 2000; 12: 107–117.
- Rosen RC, Giuliainen F, Larsen CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hypertrophy (BPH). European Urology 2005; 47: 824–837.
- Lowe FC, McConnell JD, Hudson PB et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003; 61: 791–796.
- MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 2005; 66: 780–788.
- MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU International 2004; 94: 1263–1270.
- McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine 2003; 349: 2387–2398.
- Kaplan SA, McConnell JD, Roehrborn CG et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. Journal of Urology 2006; 175: 217–220.
- Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. Journal of Urology 2005; 174: 2273–2275.
- Lee JY, Kim HW, Lee SJ et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU International 2004; 94: 817–820.
- Andersson KE, Chapple CR, Hofner K. Future drugs for the treatment of benign prostatic hyperplasia. World Journal of Urology 2002; 19: 436–442.
- Desgrandchamps F, Mongiat-Artus P. Dosage and duration of medication for men with lower urinary tract symptoms: two questions without definitive answers. Current Opinion in Urology 2006; 16: 37–39.
- Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs & Aging 1997; 10: 349–366.
- Baldwin KC, Ginsberg PC, Roehrborn CG 19. et al. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001; 58: 203–209.
- Verhamme KM, Dieleman JP, Bleumink GS et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. European Urology 2003; 44: 539–545.
- Barron R, Kotak S. Development of a patient satisfaction with treatment questionnaire for benign prostatic hyperplasia (BPH-PSTQ). Quality of Life Research 2006; 9(3): A55 (PIH117).
- Barron R. Exploratory factor analysis of a 22 13-item BPH Patient Satisfaction with Treatment Questionnaire (BPH-PSTQ). Quality of Life Research 2006; 9(3): A55 (PIH118).
- Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urology 2002; 2: 14.
- Hareendran A, Abraham L. Using a treatment satisfaction measure in an early trial to inform the evaluation of a new treatment for benign prostatic hyperplasia. Value in Health 2005; 8(Suppl. 1): S35–S40.
- Calais Da Silva F, Maquis P, Deschaseaux P et al. Relative importance of sexuality and quality of life in respondents with prostatic symptoms. Results of an international study. European Urology 1997; 31: 272–280.